Acalabrutinib Maleate Patent Expiration
Acalabrutinib Maleate is used for treating adult patients with various types of leukemia and lymphoma. It was first introduced by Astrazeneca Uk Ltd
Acalabrutinib Maleate Patents
Given below is the list of patents protecting Acalabrutinib Maleate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Calquence | US10239883 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | Jul 11, 2032 | Astrazeneca |
| Calquence | US10272083 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Jan 21, 2035 | Astrazeneca |
| Calquence | US11059829 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate | Jul 01, 2036 | Astrazeneca |
| Calquence | US11771696 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Jan 21, 2035 | Astrazeneca |
| Calquence | US7459554 | Imidazopyrazine tyrosine kinase inhibitors | Nov 24, 2026 | Astrazeneca |
| Calquence | US9290504 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors | Jul 11, 2032 | Astrazeneca |
| Calquence | US9758524 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | Jul 11, 2032 | Astrazeneca |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳